ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	Cyclovirobuxine D
Cat. No.	:	PC-24744
CAS No.	:	860-79-7
Molecular Formula	:	$C_{26}H_{46}N_2O$
Molecular Weight	:	402.67
Target	:	YAP-TEAD
Solubility	:	10 mM in DMSO



Biological Activity

Cyclovirobuxine D (CVB-D) is a naturally alkaloid, induces autophagy and attenuates the phosphorylation of Akt and mTOR, exerts its anti-cancer effects by directly binding to YAP, inhibits the nuclear translocation of YAP/TAZ and suppresses the transcription of downstream oncogenic target genes.
Cyclovirobuxine D (CVB-D) could improve cardiac dysfunction in a cecal ligation and puncture (CLP) model in rodents and in a lipopolysaccharide (LPS) model in vitro.
Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. also is an inhibitor of cytoplasmic leukemia inhibitory factor (LIF) in HCC, suppresses proliferation and metastasis by activating p38MAPK/p62-modulated mitophagy.
Cyclovirobuxine D inhibits triple-negative breast cancer via YAP/TAZ suppression and activation of the FOXO3a/PINK1-Parkin pathway-induced mitophagy.
Cyclovirobuxine D triggers autophagy to suppress the proliferation of TNBC and promote TNBC apoptosis.
Cyclovirobuxine D exhibits notable antitumor activity against diverse tumor types.

References

Gao K, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 11.

Wang ZQ, et al. Phytomedicine. 2025 Jan;136:156287.

Hu D, et al. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9.

Lu J, et al. J Pharmacol Sci. 2014;125(1):74-82.

E-mail: tech@probechem.com